Madrigal Pharmaceuticals reported a strong quarter with significant revenue growth, strategic patent extensions, and promising international and pipeline expansions. However, concerns regarding increased expenses and potential market competition somewhat temper the outlook.

Company Guidance -

Q3 2025

During Madrigal Pharmaceuticals' second quarter 2025 earnings call, several key metrics were highlighted to demonstrate the company's strong performance and strategic advancements. Rezdiffra's quarterly run rate exceeded $200 million, with second-quarter net sales reaching $213 million, marking a 55% quarter-over-quarter increase. The U.S. net sales of Rezdiffra were annualizing at over $800 million, driven by more than 23,000 patients on therapy, up from 17,000 in the previous quarter, indicating robust growth with only 7% penetration among 315,000 diagnosed F2, F3 MASH patients. Physician adoption was also strong, with 80% of the top 6,000 target prescribers now prescribing Rezdiffra. Additionally, the company secured a new U.S. patent for Rezdiffra, protecting it until February 2045, and announced plans for international expansion, starting with Germany later in the year. Madrigal also entered into an agreement for up to $500 million in a senior secured credit facility, further solidifying its financial position.

Strong Quarterly Performance

Rezdiffra delivered net sales of $213 million, up 55% quarter-over-quarter, with U.S. net sales annualizing at well over $800 million.

U.S. Patent Extension

A new U.S. patent was issued for Rezdiffra, extending protection to February 2045, providing strategic flexibility and increasing long-term value.

International Expansion Ahead

Preparations are underway for launching Rezdiffra in Germany, with a positive CHMP opinion received and approval expected soon.

Pipeline Expansion

Acquisition of SYH2086, a promising oral GLP-1 asset, for a $120 million upfront payment, targeting a combination with Rezdiffra for MASH treatment.

Physician Adoption Milestone

80% of the top 6,000 target physicians have prescribed Rezdiffra, exceeding benchmarks and indicating strong market penetration.

Strong Cash Position

Ended the second quarter with $802 million in cash and a new agreement for up to $500 million in a credit facility to support future growth.

Madrigal Pharmaceuticals (MDGL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MDGL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-2.21 / -	-4.92	―	―	―
Aug 05, 2025	2025 (Q2)	-3.55 / -1.90	-7.1	73.24% (+5.20)
May 01, 2025	2025 (Q1)	-3.75 / -3.32	-7.38	55.01% (+4.06)	―
Feb 26, 2025	2024 (Q4)	-3.92 / -2.71	-5.68	52.29% (+2.97)	―
Oct 31, 2024	2024 (Q3)	-6.75 / -4.92	-5.34	7.87% (+0.42)	―
Aug 07, 2024	2024 (Q2)	-7.54 / -7.10	-4.69	-51.39% (-2.41)	―
May 07, 2024	2024 (Q1)	-6.29 / -7.38	-4.23	-74.47% (-3.15)	―
Feb 28, 2024	2023 (Q4)	-5.24 / -5.68	-4.98	-14.06% (-0.70)	―	―
Nov 06, 2023	2023 (Q3)	-4.90 / -5.34	-4.75	-12.42% (-0.59)	―	―
Aug 08, 2023	2023 (Q2)	-4.59 / -4.69	-4.14	-13.29% (-0.55)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MDGL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$312.11	$338.91	+8.59%
May 01, 2025	$333.91	$327.70	-1.86%
Feb 26, 2025	$309.49	$355.88	+14.99%
Oct 31, 2024	$215.93	$259.34	+20.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Madrigal (MDGL) report earnings?

Madrigal (MDGL) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Madrigal (MDGL) earnings time?

Madrigal (MDGL) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MDGL EPS forecast?

MDGL EPS forecast for the fiscal quarter 2025 (Q3) is -2.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing